Copeptin as a diagnostic and prognostic biomarker in patients admitted to Emergency Department with syncope, presyncope and vertiginous syndrome.

MLA

Schiavon, Luca, et al. “Copeptin as a Diagnostic and Prognostic Biomarker in Patients Admitted to Emergency Department with Syncope, Presyncope and Vertiginous Syndrome.” Clinical Chemistry and Laboratory Medicine, vol. 56, no. 3, Feb. 2018, pp. e72–74. EBSCOhost, https://doi.org/10.1515/cclm-2017-0750.

APA

Schiavon, L., Casarotti, A., Mion, M. M., Vigolo, S., Vettore, G., Zaninotto, M., & Plebani, M. (2018). Copeptin as a diagnostic and prognostic biomarker in patients admitted to Emergency Department with syncope, presyncope and vertiginous syndrome. Clinical Chemistry and Laboratory Medicine, 56(3), e72–e74. https://doi.org/10.1515/cclm-2017-0750

Chicago

Schiavon, Luca, Alessandra Casarotti, Monica M Mion, Stefania Vigolo, Gianna Vettore, Martina Zaninotto, and Mario Plebani. 2018. “Copeptin as a Diagnostic and Prognostic Biomarker in Patients Admitted to Emergency Department with Syncope, Presyncope and Vertiginous Syndrome.” Clinical Chemistry and Laboratory Medicine 56 (3): e72–74. doi:10.1515/cclm-2017-0750.